Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

PURPOSE: HER2-positive breast cancer is heterogeneous. Some tumors express mutations, like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with response to HER2-targeted therapies. In this exploratory analysis, we investigated whether the efficacy of trastuzumab emt...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Baselga, José, Lewis Phillips, Gail D., Verma, Sunil, Ro, Jungsil, Huober, Jens, Guardino, Alice E., Samant, Meghna K., Olsen, Steve, de Haas, Sanne L., Pegram, Mark D.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5485412/
https://ncbi.nlm.nih.gov/pubmed/26920887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2499
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы